📰 Updated Clinical Data News
Updated Clinical Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Updated Clinical Data. Real-time updates on events, politics, business and more.
May 11, 2023
11.05.2023 - – Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND (mitapivat) on Hemoglobin, Hemolysis, Iron Overload and Patient-Reported Outcomes – – ... Seite 1
June 7, 2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The ...
May 18, 2022
Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI
April 28, 2022
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. (“Rubius” or the...
April 23, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...
April 23, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...
April 15, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
April 11, 2022
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. . Such investors are advised to contact... | April 11, 2022
April 11, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...